Loading...
•
Jun 30, 2025
Agios Q2 2025 Earnings Report
Agios reported its second quarter 2025 financial results, highlighting increased PYRUKYND net revenues and progress in its clinical pipeline.
Key Takeaways
Agios Pharmaceuticals reported a net loss of $112.0 million in Q2 2025, an increase from $96.1 million in Q2 2024. Despite the loss, the company saw a significant increase in PYRUKYND net product revenue, reaching $12.5 million, up from $8.6 million in the prior year. The company ended the quarter with $1.3 billion in cash, cash equivalents, and marketable securities.
PYRUKYND net product revenue increased to $12.5 million in Q2 2025, up from $8.6 million in Q2 2024.
The company reported a net loss of $112.0 million for the second quarter of 2025.
Agios ended the second quarter with $1.3 billion in cash, cash equivalents, and marketable securities.
The sNDA for PYRUKYND in thalassemia is under active FDA review with a PDUFA goal date of September 7, 2025.
Revenue by Segment
Forward Guidance
Agios is focused on the potential U.S. approval of PYRUKYND for thalassemia and expects topline results from the RISE UP Phase 3 trial for PYRUKYND in sickle cell disease by year-end, with a potential U.S. commercial launch in 2026. The company also initiated a Phase 2 trial for tebapivat in sickle cell disease and received IND clearance for AG-236.
Positive Outlook
- PYRUKYND sNDA for thalassemia under active FDA review with PDUFA goal date of September 7, 2025.
- Topline results from RISE UP Phase 3 trial of mitapivat in sickle cell disease on track by year-end.
- Potential U.S. commercial launch of PYRUKYND in sickle cell disease in 2026.
- First patient dosed in the tebapivat Phase 2 sickle cell disease trial.
- Received IND clearance for AG-236 for the treatment of polycythemia vera.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the report.
- Increased R&D expenses due to a regulatory milestone payment.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...